Immunomedics Inc logo

IMMU - Immunomedics Inc Share Price

$87.86 0.0  0.0%

Last Trade - 7:10pm

Large Cap
Market Cap £15.44bn
Enterprise Value £14.70bn
Revenue £15.5m
Position in Universe 472nd / 6440
Unlock IMMU Revenue
Relative Strength (%)
1m -0.99%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High 0.000
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
5.65 3.23 3.09 2.16 0.000 0.30 126.5 308.1 -44.6%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Immunomedics, Inc. revenues increased from $0K to $20.1M. Net loss decreased 2% to $159.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development decrease of 5% to $105M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.85 to -$0.73.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for IMMU
Graphical History


IMMU Revenue Unlock IMMU Revenue

Net Income

IMMU Net Income Unlock IMMU Revenue

Normalised EPS

IMMU Normalised EPS Unlock IMMU Revenue

PE Ratio Range

IMMU PE Ratio Range Unlock IMMU Revenue

Dividend Yield Range

IMMU Dividend Yield Range Unlock IMMU Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IMMU EPS Forecasts Unlock IMMU Revenue
Profile Summary

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated July 6, 1982
Public Since April 12, 1984
No. of Shareholders: 328
No. of Employees: 366
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 231,156,742
Free Float (0.0%)
Eligible for
IMMU Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IMMU
Upcoming Events for IMMU
Wednesday 28th October, 2020 Estimate
Q3 2020 Immunomedics Inc Earnings Release
Thursday 25th February, 2021 Estimate
Q4 2020 Immunomedics Inc Earnings Release
Frequently Asked Questions for Immunomedics Inc
What is the Immunomedics Inc share price?

As of 7:10pm, shares in Immunomedics Inc are trading at $87.86, giving the company a market capitalisation of £15.44bn. This share price information is delayed by 15 minutes.

How has the Immunomedics Inc share price performed this year?

Shares in Immunomedics Inc are currently trading at $87.86 and the price has moved by 0.446k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Immunomedics Inc price has moved by 0.376k% over the past year.

What are the analyst and broker recommendations for Immunomedics Inc?

Of the analysts with advisory recommendations for Immunomedics Inc, there are there are currently 1 "buy" , 6 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Immunomedics Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Immunomedics Inc next release its financial results?

Immunomedics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Immunomedics Inc dividend yield?

Immunomedics Inc does not currently pay a dividend.

Does Immunomedics Inc pay a dividend?

Immunomedics Inc does not currently pay a dividend.

When does Immunomedics Inc next pay dividends?

Immunomedics Inc does not currently pay a dividend.

How do I buy Immunomedics Inc shares?

To buy shares in Immunomedics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Immunomedics Inc?

Shares in Immunomedics Inc are currently trading at $87.86, giving the company a market capitalisation of £15.44bn.

Where are Immunomedics Inc shares listed? Where are Immunomedics Inc shares listed?

Here are the trading details for Immunomedics Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: IMMU
What kind of share is Immunomedics Inc?

Based on an overall assessment of its quality, value and momentum, Immunomedics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Immunomedics Inc share price forecast 2020?

Shares in Immunomedics Inc are currently priced at $87.86. At that level they are trading at 13.89% premium to the analyst consensus target price of 0.00.

Analysts covering Immunomedics Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.114 for the next financial year.

How can I tell whether the Immunomedics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immunomedics Inc. Over the past six months, the relative strength of its shares against the market has been 0.158k%. At the current price of $87.86, shares in Immunomedics Inc are trading at 0.139k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Immunomedics Inc PE Ratio?

We were not able to find PE ratio data for Immunomedics Inc.

Who are the key directors of Immunomedics Inc?

Immunomedics Inc's management team is headed by:

Behzad Aghazadeh - CHM
Scott Canute - EDR
Peter Hutt - IND
Khalid Islam - IND
Brendan Delaney - OTH
Usama Malik - CFO
William Fricker - CAO
Jared Freedberg - GCN
Charles Baum - IND
Barbara Duncan - IND
Kurt Andrews - CHO
Bryan Ball - OTH
Loretta Itri - OTH
Robert Azelby - IND
Who are the major shareholders of Immunomedics Inc?

Here are the top five shareholders of Immunomedics Inc based on the size of their shareholding:

Avoro Capital Advisors LLC Investment Advisor/Hedge Fund
Percentage owned: 11.36% (26.3m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.16% (18.9m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.86% (11.2m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 4.79% (11.1m shares)
T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 2.98% (6.88m shares)
Similar to IMMU
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.